

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ACQUISITION OF PROPERTY IN THE US AND ESTABLISHMENT OF THE US SUBSIDIARY ETHK BANK ADVANCING NEW INITIATIVES IN STABLECOINS AND INTELLECTUAL PROPERTY SECURITIZATION IN THE US

This announcement is made by IVD Medical Holding Limited (the “**Company**” or “**IVD**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders and potential investors with an update of the latest business development of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has recently completed the acquisition of a property located in Irvine, Orange County, California, United States (“**US**”) (the “**Property**”) for a total consideration of US\$4.365 million. Concurrently, the Company has incorporated ETHK BANK Inc. (“**ETHK BANK**”, Registration ID: 20251886812) as a wholly-owned subsidiary in the State of Colorado, US, which will serve as a key platform for the Group to develop its stablecoin, healthcare, and innovative drug intellectual property securitization exchange-related businesses in the North American market.

This represents the Group’s strategic deployment in response to global trends in digital finance and intellectual property securitization, leveraging North America’s mature regulatory environment and innovative asset market potential. It aims to further enhance the Group’s global business synergy capabilities and create sustainable long-term value for shareholders and investors.

I. PROPERTY ACQUISITION: ESTABLISHING A PRESENCE IN NORTH AMERICA’S CORE LOCATION TO SOLIDIFY THE GLOBAL BUSINESS ENTITY HUB

The parcel number for the Property is APN 588-206-19, located at 9840 Irvine Center Drive, Irvine, Orange County, California, US (ZIP Code: 92618). The total land area is approximately 4,960 square feet (approximately 0.113 acres), including a two-story office building of approximately 9,920 square feet. It encompasses office spaces, meeting rooms, and supporting facilities, serving both office and research and development (“**R&D**”) purposes.



The Property will be developed as the Group’s strategic headquarters in the US, focusing on supporting stablecoin public blockchain technology R&D and innovative capital operations such as intellectual property securitization. It will establish a physical hub connecting global innovation assets with capital markets, achieving the implementation of a full-chain business ecosystem “from knowledge to capital”. This will provide an efficient and transparent conversion platform for realizing the value of intangible assets.

II. ETHK BANK: BUILDING A GLOBAL FLAGSHIP PLATFORM FOR STABLECOIN AND INTELLECTUAL PROPERTY SECURITIZATION OPERATIONS

ETHK BANK will serve as the Group’s global operational platform for stablecoin and intellectual property securitization businesses, centrally managing the following core business directions:

- **Stablecoin license applications and compliance framework development:** Leveraging the federal regulatory framework established under the US GENIUS Act, we are actively advancing the application for a federal qualified payment stablecoin issuer license. Concurrently, we plan to apply for a National Trust Bank License from the Office of the Comptroller of the Currency (OCC) to build a compliant operational system meeting 1:1 reserve requirements (such as cash and US Treasury bonds), providing secure and reliable financial infrastructure for the digital asset ecosystem;
- **Innovative stablecoin public chain technology R&D:** The Group is developing an industry-leading stablecoin underlying architecture featuring multi-asset segregation design, enabling organic synergy among payment medium, yield rights, and governance rights. This architecture enables users to generate stablecoins pegged 1:1 to the US dollar by collateralizing real-world assets (“RWA(s)”) such as US Treasuries, while dynamically capturing underlying asset yields through non-fungible token (“NFT”) rights certificates, truly realizing the innovative “Stable-to-Earn” mechanism. This technology aims to reshape stablecoin value distribution models, offering users a transparent, autonomous, and sustainable digital asset yield solution;

- **Establishment of an innovative drug intellectual property securitization exchange:** building the world’s first specialized trading platform dedicated to tokenizing innovative drug intellectual property, facilitating market circulation and value discovery of cutting-edge medical R&D outcomes, and pioneering new avenues for global investors to allocate top-tier healthcare assets;
- **Ecosystem synergy and strategic expansion:** planning to continuously enhance the stablecoin and intellectual property securitization business ecosystem in the future through strategic investments or acquisitions of compliant financial institutions, thereby elevating the Group’s comprehensive service capabilities and resource integration efficiency within the global digital finance sector.

Additionally, the Group’s existing deployment of RWA-related businesses in the Chinese Mainland and Hong Kong region—including the development of a global RWA exchange technology ecosystem, the “ETHK Global RWA Exchange – Exchange within Exchange” model, RWA technology R&D, and the “ETHK On-Chain Financial Ecosystem” strategy encompassing stablecoins and Web3—will be progressively integrated into ETHK BANK to achieve optimized global resource allocation and effective risk management.

III. PROGRESS ON KEY COOPERATION PROJECTS: STEADY ADVANCEMENT OF RWA FLAGSHIP PROJECT FOR TOP-TIER INNOVATIVE DRUG ASSETS

The strategic cooperation agreement signed between the Group and Transcenta Holding Limited (“**Transcenta Group**”, stock code: 06628.HK) and its subsidiary Transcenta Oncology Inc. (US) (collectively referred to as the “**Transcenta Parties**”), involving the RWA tokenization of innovative drug pipeline assets with a value of approximately US\$1.5 billion, is currently being advanced under the leadership of ETHK BANK. Currently, the project is well under way and in line with the planned schedule.

The assets involved in this project represent cutting-edge R&D directions in the global oncology field, featuring high technological barriers. It is expected to provide global investors with a transparent and professional channel for medical asset allocation, thereby accelerating the development of innovative therapies and ultimately benefiting patients worldwide.

IV. FUTURE OUTLOOK: A GLOBAL LEADER IN HIGH-TECH INTELLECTUAL PROPERTY CAPITAL OPERATIONS

Through the acquisition of the Property in the US and the establishment of ETHK BANK and the active advancement in the R&D of stablecoin public chain technology, the Group is steadily advancing its strategic upgrade to become a globally leading stablecoin and high-tech intellectual property capital operator, committed to driving the in-depth integration of on-chain financial infrastructure with the real economy. The Board believes this initiative not only aligns with global trends in digital economy and fintech innovation, but also promises to open new growth pathways for the Group, facilitating the value identification and efficient circulation of premium global assets.

This transaction and business restructuring align with the Group's overall development strategy. However, future operations may be subject to uncertainties arising from market conditions, regulatory policies, and international relations. The Board will continuously assess relevant risks and safeguard shareholder interests through robust governance mechanisms.

The Board believes this initiative embodies the Group's core philosophy of "from knowledge to capital". Through professional, compliant capital operations and innovative practices, it will drive the transformation of intangible assets into core capital, creating long-term, stable returns for shareholders.

By order of the Board
IVD Medical Holding Limited
Lin Xianya
Executive Director

Hong Kong, 13 October 2025

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Mr. Law Kim Fai, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and five independent non-executive directors, namely, Dr. Zhong Renqian, Dr. Wong Sze Lok, Ms. Tai Yang, Mr. Xu Da and Mr. Zhang Jianlei.

This announcement may contain certain forward-looking statements that reflect the Group's beliefs, plans or expectations about the future. These statements are based on a number of assumptions, current estimates and projections, and subject to inherent risks, uncertainties and other factors which may or may not be beyond the Group's control. The actual outcomes may differ. Nothing contained in these statements is, or shall be, relied upon as any assurance, representation or warranty otherwise. Neither the Group nor its directors, staff, agents, advisers or representatives assume any responsibility to update, supplement, correct these statements or adapt them to future events.

If there are any inconsistency between the Chinese and English versions of this announcement, the Chinese version shall prevail.